CAMBRIDGE, Mass. — ARIAD Pharmaceuticals has named Martin J.
Duvall as senior vice president, commercial operations, according to a press
Duvall will be responsible for leading the global
commercialization of ARIAD''s innovative oncology drug candidates, including its
investigational pan-BCR-ABL inhibitor, ponatinib, which is in a pivotal Phase 2
clinical trial in patients with resistant or intolerant chronic myeloid
leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.
has demonstrated unequivocal success in both U.S. and international oncology
leadership roles, working in both large pharmaceutical and mid-sized
biotechnology companies on drugs to treat both solid tumors and hematological
cancers,” said Harvey J. Berger, chairman and CEO of ARIAD. “He has the global
experience, leadership skills and dedication that we need to maximize the value
of ponatinib and our pipeline of oncology drug candidates for our shareholders
and the entrepreneurial know-how needed to build a ''second-to-none'' commercial